Abbott Sharpens Focus On Higher-Margin Products, Spins Off Hospital Unit
This article was originally published in The Gray Sheet
Executive Summary
Abbott will refocus resources on advanced technologies including stents and spinal fusion systems after divesting the lion's share of its slower-growth hospital products unit in a spin-off to shareholders
You may also be interested in...
Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz
Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.
Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz
Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.
Abbott Vascular Ripens With Anticipated 2005 Launches Of Stent, Sealant
Rapid hospital discharges associated with Abbott's StarClose will favor the device over manual femoral access closure methods upon launch in the second half of 2005, the firm claims